Drug-coated balloons (DCBs) are frequently used to treat in-stent restenotic lesion of coronary artery disease in countries where they are available. However, how DCBs affect the neointimal characteristics is poorly understood.

A 79-year-old man with multiple coronary risk factors (diabetes, dyslipidemia, hypertension, and smoking) had received 2 bare metal stents 20 years before, a sirolimus-eluting stent 12 years before, and a paclitaxel-eluting stent 10 years before at the proximal left anterior descending artery for repeated restenosis ([Fig. 1](#fig1){ref-type="fig"}A1). Because the patient developed late stent thrombosis, a DCB (Sequent Please Paclitaxel-eluting Balloon 3.0/30, B. Braun Medical Inc., Melsungen, Germany) was used to treat this lesion after thrombus aspiration and predilation with a scoring balloon (NSE 2.75/13, NIPRO, Osaka, Japan). One year later, follow-up optical frequency domain imaging was obtained. [Figure 1](#fig1){ref-type="fig"} shows the angiography and optical frequency domain imaging findings before DCB treatment, after DCB treatment, and 1 year after DCB treatment at the matching slice. Of note, what had been relatively homogenous neointima proximal to the culprit site showed newly formed lipid-laden neointima and even neointimal calcification in just 1 year ([Fig. 1](#fig1){ref-type="fig"}B1-3 and C1-3). The thrombus site showed multiple levels of healing ([Fig. 1](#fig1){ref-type="fig"}D1-3 and E1-3). The neointimal characteristics showed dynamic changes after DCB treatment.Figure 1Corresponding optical frequency domain imaging and angiography findings at different timings are shown: before drug-coated balloon (DCB) treatment (**A1-E1**), after DCB treatment (**A2-E2**), and 1 year after DCB treatment (**A3-E3**). **Arrowheads** in B3 and C3 indicate newly formed calcification and lipid-laden neointima. C, calcification; Th, thrombus.

In-stent atherosclerotic change (neoatherosclerosis) after drug-eluting stent implantation is not rare.[@bib1] One of the mechanisms seems to be alteration of endothelial barrier protein expression by antiproliferative drugs,[@bib2] which may also happen for paclitaxel used in DCB.[@bib3] Further studies in a case series would be helpful to understand the frequency and pathophysiology of neoatherosclerosis after DCB.Novel Teaching Point•Drug-coated balloons might have a potential to accelerate neoatherosclerosis.
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